

Evolution in action: lessons from antimalarial resistance

Dr. Charles Woodrow PhD MRCP

Mahidol University–Oxford Tropical
Medicine Research Unit (MORU)

3rd December 2010

ORIGINAL ARTICLE


Artemisinin Resistance in *Plasmodium falciparum* Malaria

Aye M. Dondor, M.D., François Nosten, M.D., Porawuth V., M.D.,
Dabathish Dai, M.D., Aung Phean Fyoo M.D., Joel Tarning, F.R.D.,
Khin Maung Lwin M.D., Fredrick Ariey M.D., Waranya Hantrakpong P.D.,
Sue J. Lee P.D., Pascal Ingwand M.D., Kamolrat Silamar, Ph.D.,
Maha Sawong, P.D., Kesinee Chobvongch, Ph.D., Phuchit Wan, M.D.,
Tran Ferdman P.D. Sen Sam An, Shunmay Young, Ph.D.,
Prasat Singhasivanon, M.D., Nicholas P., Day J.M. Nicolas L. Neegard, F.R.D.,
Dung Socheat, M.D. and Nicholas J. White, F.R.S

Chloroquine resistance in *Plasmodium vivax*

Molecular understanding

- Hundreds of pathogen, host and vector genomes sequenced
- Increasing individual genomes 'resequenced'



Plasmodium falciparum genome

- 23 million bases in nuclear genome
- 14 chromosomes
- >5000 genes

- Non-globular domains within proteins

“Non-globular” domains

Proteins or domains that do not assume compact, folded structures



Chromosome 2 Sequence of the Human Malaria Parasite *Plasmodium falciparum*

Malcolm J. Gardner, Hervé Tottelin, Daniel J. Carucci,
Leda M. Cummings, L. Aravind, Eugene V. Koenig,
Shamira Shallom, Tanya Mason, Kelly Yu, Claire Fujii,
James Pedersen, Kun Shun, Junping Jing, Christopher Aston,
Zhongwu Lai, David C. Schwartz, Mihaela Fertea,
Steven Salzberg, Lixin Zhou,* Granger G. Sutton,†
Rebecca Clayton, Owen White, Hamilton O. Smith,†
Claire M. Fraser, Mark D. Adams,† J. Craig Venter,†
Stephan L. Hoffman‡

- 155/209 proteins had large **nonglobular** domains
– expressed
- ‘... the *Plasmodium* genome sequence should provide broader biological insights, particularly in regard to ... the preponderance of the predicted **nonglobular** domains in plasmodial proteins.’

PFE0195w amino acids 1-500

MARFCKSDKLLINHRELKYICLFYIILLFCFFLWCIFKKYHENRINRKHKR
KGSDDSHKNEKTEFFNYIYESYNDNDDVIRQEGYKNSLCGFLKKNISIVL
YLLTHFIIILLIGNEYCIKENGEILWNDRAFVFFIFLLLCFIITYGILTVR
KHMHSFFIKPSLLKDSYVLVYTKNEDYTNSYKNIFKESYVYITNVFIKWN
KKIYKYSCKYIKLLHYYQMNAKSFFFFISTD**KKKKK**NDYIKNSYHDDDLDD
DDIQNKDNNNYYSNIYKKNSYNNNSFHKKSISNQYSNKRLSRNSLYTKKV
LRDQENNLGYDQDQNEINKMNSIDHIYNI DSLNVIDQGNDKNYDNEEKEI
NKKYPFNRN**DEYGDEYGDEYGDEYGNKYGNKYGNKYDDKYGNKYDDKYDDK**
YDDKYDDKYDDKYDDKYDDKYDDKYDDKYDDNIVWGSKRFSN**KKKKKGKKK**
RKNEMV TSAQTNREYIENNLKVHKVKVRINEKNVRYFFFRS...

Pf non-globular domains 1998-2010

No function documented
Deletion generally tolerated
Missing sections in crystals
Prone to SNPs and indels

'Neutral'


v

'Adaptive'

SNPs and indels increasingly implicated
in drug-resistance phenotypes
artemisinin
quinine
doxycycline

A photograph of a foggy landscape. In the center, a utility pole stands with several power lines extending across the sky. The ground is covered in a layer of snow or frost, and the background shows faint silhouettes of trees. The overall atmosphere is misty and grey.

The fog of information can drive
out knowledge



Neutral evolution

"Variations neither useful nor injurious would not be affected by natural selection, and would be left a fluctuating element"

On the Origin of Species


1859

Neutral theory develops




- Kimura 1967
- King and Jukes
- At the molecular level, evolution is mostly neutral
 - e.g. synonymous mutations
 - non-synonymous mutations in haemoglobin
- Generally accepted
 - ? quantitative contribution to molecular evolution

3 'directions' of selection



Kimura:
Molecular evolution over aeons of time



Genetic drift

Adaptive mutation



Adaptive change in natural world




? **Neutral** change in natural world

Loss of function

Cave salamander



Ostrich



Kakapo



Thai angel cave fish



What causes loss of function?

- Positive (adaptive)
 - Eyes are costly to make and can get infected
 - Wings are costly to grow and use up a lot of energy

Mutations constantly bombard genome




Neutral perspective

- Genotype
 - Gene is freed from selective forces
- Under mutational bombardment
 - Non-synonymous polymorphism as common as synonymous
 - Insertion of stop codons (pseudogene)
- **Phenotype**
 - **Eyes and wings are lost because negative selection is not maintained**

Exploring neutral theory in infectious diseases


First drugs against HIV



- Inhibit reverse transcriptase
- Nucleoside reverse transcriptase inhibitors (NRTIs)
- Resistance : predictions from neutral theory
 - Conservation of amino acid residues involved in drug-binding site
 - Resistance emerges via mutation at conserved residues
 - Fitness cost

How do we test this?

- Use evolutionary comparison
- Compare to orthologous sequences from other species
 - HIV-2, etc.



Lentivirus reverse transcriptases

HIV1.prot	1	-PISPIDTVPVTLKPGMDGPKVKQWPLTEEEKIKALTEICKEMEKEGKISKIGPENPYNTP	59
Equine IA.prot	1	-----LTTAHYNRLKYRGRKYQGTGIIGVGGNVETFSTP	34
FIV.prot	1	-----LSNEKIEALTDIVERLESEGKVKRADPNNPWNTP	34
SIV.prot	1	-PIAKVEPVKVTLKPGKDGPKLRQWPLSKEKIVALREICEKMEKDGQLEEAPPTNPYNTP	59
HIV2.prot	1	MAVAKVEPIKIMLKPGKDGPKLRQWPLTKEKIEALKEICEKMEKEGQLEEAPPTNPYNTP	60
		* . . * . * . **	
HIV1.prot	60	VFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLVDVGDAYFSVP	119
Equine IA.prot	35	VTIKKKGRHIKTRMLVAD-----IPVTILGRDILQDLGAKLVLAQLSKEIKFRKIE	85
FIV.prot	35	VFAIKKKSQ-KWRMLIDFRVLNKLTDKGAEVQLGLPHPAGLQMKKQVTVLDIGDAYFTIP	93
SIV.prot	60	TFAIKKKDKNKWRMLIDFRELNKVTQDFTEVQLGIPHPAGLAKRKRITVLDVGDAYFSIP	119
HIV2.prot	61	TFAIKKKDKNKWRMLIDFRELNKVTQDFTEIQLGIPHPAGLAKRKRITVLDVGDAYFSIP	120
		** * * * . ** * . . * . .	
HIV1.prot	120	LDESEFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSFAIFQSSMTKILEPFRIKNPEMV	179
Equine IA.prot	86	LKEGTMGPKIPQWPLTKEKLEGAKEIVQRLLSEGKISEASDNNPNYNSPIFVIKKKSGKWR	145
FIV.prot	94	LDPDYAPYTAFTLPRKNNAGPGRRYVWCSPQGWVLSPLIYQSTLDNILQPFIKQNPELD	153
SIV.prot	120	LDEEFRQYTAFTLPSVNNAEPGKRYIYKVLPQGWKGSFAIFQHTMRNVLEPFRKANPDVT	179
HIV2.prot	121	LHEDFRPYTAFTLPSVNNAEPGKRYIYKVLPQGWKGSFAIFQHTMRQVLEPFRKANKDVI	18
		* . * * * . * * . .	

Resistance to NRTIs determined by RT K65R

Drug resistance in highly conserved location

Fitness cost


Principle seems to apply

Non-globular regions in *P. falciparum*:


Methods to define non-globular regions

- (Informational complexity)
- **Evolution**
 - Other *Plasmodium* species genomes now available
 - *P. chabaudi* (rodent)
 - Conservation score across ortholog
- Note hydrophilicity to add structural component


HIV Reverse Transcriptase






Pf hexose transporter



PFE0195w







Examine non-synonymous fixed
differences within clade

P. falciparum (human) vs.
P. reichenowi (chimpanzee)

Pf hexose transporter




PFE0195w



Extension to 40 genes

- Fixed differences between *P. falciparum* and *P. reichenowi* follow neutral theory
 - Genetic drift
- Most mutations appear to be in non-globular regions
 - Non-synonymous mutation 20 times more common than in globular regions

Genetic drift appears most common form of mutation



Functional mutations

- Should show opposite pattern

Functional mutations
in enzymes


=

Drug-resistance
mutations

- Drug-resistance also most practical application

Test approach in HIV reverse transcriptase

NRTI mutations




Apply to known antimalarial resistance loci


Compare **sensitive** and **resistant** strains

Chloroquine resistance locus




HB3 vs. Dd2[®] nSNPs



DHFR locus 3D7 vs. Dd2



DHPS locus, HB3 v. Dd2



Performance

- Tested in other independent isolate pairs
- Sensitivity / specificity not straightforward because usually >1 mutation
- Accuracy appears $\geq 95\%$

Conclusion

- *Plasmodium* proteins are rich in non-globular domains
- Most polymorphism occurs within these (genetic drift)
 - Last place to look for functional mutations
- Conserved regions
- Pairwise non-synonymous mutations are very rare
- Known drug resistance mutations are conspicuous in their occurrence in highly conserved regions
- Such regions have experienced more mutation in decades of drug use than millions of years of natural selection

Thank you

Kate Gardner

Ipsita Sinha

Nick Day

Nick White

(MORU)

Leyla Bustamante

(Sanger, UK)